ClinicalTrials.gg
RecruitingNCT05562505REDEEMUpdated Aug 9, 2024

Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure

An interventional study of Venovenous ECMO in Mechanical Ventilation Complication, Hypoxemia and Acute Respiratory Distress Syndrome Due to COVID-19, sponsored by Australian and New Zealand Intensive Care Research Centre. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Australian and New Zealand Intensive Care Research Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hypoxia with a site in Australia — 3 open to participants now, 3 under way, none of them phase 3. Hypoxia · Australia.

Planned enrollment
2nd of 10
140 · median 28
Started
2022
the only one that year
No phase
7 of 10
3 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Australian and New Zealand Intensive Care Research Centre

Among the 10 studies in Hypoxia with a site in Australia, this one is the 2nd largest by planned enrollment, is the only one that started in 2022, is one of 7 with no phase, and was the 7th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

3 of the 10 studies in Hypoxia with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hypoxia with a site in Australia, or all of them as a file.
02

Study summary

To determine whether a strategy of adding venovenous ECMO to mechanical ventilation, as compared to mechanical ventilation alone, increases the number of intensive care free days at day 60, in patients with moderate to severe acute hypoxic respiratory failure.

Read the detailed description

Mechanically ventilated patients with moderate to severe acute hypoxic respiratory failure are at increased risk of dying, short and long-term health problems and are often very costly to treat. The mechanical ventilator, whilst often lifesaving, may harm patients in two ways i) directly via damage to the lungs (termed ventilator induced lung injury), and ii) indirectly via paralysis and sedation that patients require to tolerate mechanical ventilation. Paralysis and sedation can increase the risk of secondary infections, weakness, prolonged duration of intensive care, as well as long-term physical disability. There is a need to develop new treatments that support patients and at the same time reduce these complications.

Extracorporeal membrane oxygenation (ECMO) is a device that supports the lungs by adding oxygen and removing carbon dioxide from the blood. By providing non pulmonary gas exchange, veno-venous (VV) ECMO can reduce the need for the mechanical ventilator. This in turn can reduce the risk of lung damage, and also removes the need for sedating medications so that activities like physiotherapy can begin earlier.

The REDEEM trial is a phase 2, investigator initiated, multicentre randomised controlled trial that will recruit 140 patients with moderate to severe acute hypoxic respiratory failure. It is designed to test whether adding ECMO to the mechanical ventilator, as compared to using the mechanical ventilator on its own, leads to an increase in the number of patients who survive and are discharged earlier from the intensive care unit. If the REDEEM trial confirms adding ECMO is more effective than mechanical ventilation alone, it has the potential to change the current paradigm of intensive care treatment of hypoxic respiratory failure, and could lead to changes in practice globally.

03

Conditions studied

  • Mechanical Ventilation Complication
  • Hypoxemia
  • Acute Respiratory Distress Syndrome Due to COVID-19
  • COVID-19 Respiratory Infection
  • Pneumonia
  • Extracorporeal Membrane Oxygenation

Keywords

  • Intensive Care Unit
  • ECMO
  • Extracorporeal Membrane Oxygenation
  • Mechanical Ventilation
  • Early ECMO
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 to 65 years old
  2. Acute hypoxemic respiratory failure characterised by new or worsening respiratory symptoms developing within 2 weeks prior to the onset of need for oxygen or respiratory support
  3. Mechanical ventilation of \<7 days
  4. Moderate to severe respiratory failure, as demonstrated by two P:F ratios \<150mmHg at least 6 hours apart. Arterial Blood Gases (ABG) with P:F ratio > 150mmHg are permitted between the two trial inclusion ABGs.
  5. Trial of proning (unless )

Exclusion criteria

Exclusion Criteria:

  1. The patient will be extubated today or tomorrow (i.e. will not remain intubated and ventilated the day after tomorrow)
  2. Cardiogenic cause of respiratory failure
  3. Chronic hypercapnic respiratory failure defined as PaCO2 > 60 mmHg in the outpatient setting
  4. Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP/BIPAP used solely for sleep disordered breathing
  5. Confirmed diffuse alveolar haemorrhage from vasculitis
  6. Neurologic conditions, i.e. undergoing treatment for intracranial hypertension
  7. Currently receiving any form of ECMO (e.g., venovenous, venoarterial, or hybrid configuration)
  8. Patient needing immediate VV ECMO (as per EOLIA criteria)
  9. The patient is moribund and deemed unlikely to survive past 24 hours (as determined by the clinical team)
  10. The patient is being transitioned to palliative care
  11. to anticoagulation (e.g., active GI bleeding, bleeding predisposition, severe trauma)
  12. Previous /anaphylactic reaction to heparin or heparin-induced thrombocytopenia
  13. Participation or Consent is declined, OR
  14. Unable to identify or Contact surrogate decision maker.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Venovenous ECMO

    Patients allocated to the ECMO strategy be initiated on V-V ECMO and on anticoagulation (blood thinning medication to prevent clot formation) within 24 hours of being allocated into the intervention group. Anticoagulant medication to prevent clot formation will be initiated as per current local practice for each site. Sites are encouraged to use best practice ECMO management that includes de-sedation, extubation, commencement of physiotherapy and rehabilitation,

    Other: Venovenous ECMO

  • No intervention
    Standard care

    Patients allocated to the standard care arm will receive routine intensive care for hypoxic respiratory failure, including mechanical ventilation as per local practices, weaning of sedation and assessment for extubation. Patients who continue to deteriorate will be eligible for initiation of V-V ECMO if they meet the ECMO to rescue lung injury in severe ARDS (EOLIA) criteria: Partial pressures of arterial oxygen (PaO2):Fraction of inspired oxygen (FiO2)\<50 for 3 hours, PaO2:FiO2\<80 for 6 hours, pH\<7.25 with PaCO2 \>60 for \>6 hours.

Interventions

  • OtherVenovenous ECMO

    ECMO therapy for patients with hypoxic respiratory failure.

06

What researchers measure

Primary outcomes

  1. Intensive Care Unit Free days to Day 60

    Days alive and free from ICU to Day 60. Day Day 0 is randomisation day, with any portion of a day is spent in an ICU counted as a day.

    Time frame: 60 Days

Secondary outcomes

  1. Daily sedation scores

    Highest (+4 Combative) and lowest (-5 Unarousable) daily Richmond Agitation and Sedation Scores (RASS). The optimal score for early mobilisation of participants on ECMO is 0 Alert and Calm.

    Time frame: Day 28

Other outcomes

  1. Extubation rates

    Date and time of enduring extubation

    Time frame: Day 28

  2. Participation in early mobilisation

    Daily assessment for mobilisation by allied health clinicians using the ICU Mobility Scale. The ICU Mobility Scale ranges from 0-Lying in Bed, to 10-Walking Independently without a Gait Aid. Score 7-Walking With the Assistance of 2 or More People is the best outcome achievable for participants on ECMO.

    Time frame: Day 28

  3. Number of Participants who were randomised to standard care initially and subsequently needed VV-ECMO.

    Number of Participants who were randomised to standard care initially and subsequently needed VV-ECMO.

    Time frame: Day 28

  4. WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)

    Assessment of 6 domains of functioning for participants at Day 180 follow up via telephone interview. Total possible scores are 48. A lower score indicates a better outcome.

    Time frame: Day 180

  5. EuroQol EQ5D-5L

    Health-related quality of life reported via telephone interview at Day 180 using the EuroQol EQ5D. Total possible scores are 25. A lower score indicates a better outcome.

    Time frame: Day 180

07

Study locations

6 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The Management Committee support the view of the International Committee of Medical Journal Editors and the World Health Organisation (WHO) with reference to the ethical obligation to responsibly share data acquired by interventional clinical trials. At the conclusion of the study, the management committee will consider requests from researchers who provide a methodically sound scientific proposal as per the Data Sharing Policy set out in the Australian and New Zealand Intensive Care Research Centre (ANZIC-RC) Terms of Reference. Only de-identified data will be shared and all requests for data must comply with the ethical, regulatory, and legislative requirements governing their jurisdiction.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jul 2026, 44 months after the start.

Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 44 months is above that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2022
First posted
Sep 30, 2022
StartActual
Nov 28, 2022
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05562505
Lead sponsor
Australian and New Zealand Intensive Care Research Centre
Collaborators
The Alfred
Responsible party
Sponsor
First posted
Sep 30, 2022
Start date
Nov 28, 2022
Primary completion
Jul 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Aug 9, 2024

Study contacts

Stephanie M Hunter
Contact
Stephanie.Hunter@monash.edu
+61 3 9903 0646
Tony Trapani
Contact
Tony.Trapani@monash.edu
+61 3 9903 0343
Aidan Burrell, MBBS
principal investigator · Monash University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion